Eli Lilly & Co.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $15.35B | $8.98B | $3.82B |
| FY2022 | $14.74B | $10.65B | $2.07B |
| FY2023 | $18.32B | $10.77B | $2.82B |
| FY2024 | $28.53B | $14.27B | $3.27B |
| FY2025 | $40.87B | $26.54B | $7.27B |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $15.35B | $8.98B | $3.82B |
| FY2022 | $14.74B | $10.65B | $2.07B |
| FY2023 | $18.32B | $10.77B | $2.82B |
| FY2024 | $28.53B | $14.27B | $3.27B |
| FY2025 | $40.87B | $26.54B | $7.27B |